

CLAIMS**What is claimed is:**

1. A pharmaceutical composition, comprising: a therapeutically effective amount of a salt of flecainide, wherein said pharmaceutical composition is in the form of a liquid solution that has said salt of flecainide at a concentration above 60 mg/mL.
2. The pharmaceutical composition of claim 1, further comprising a cyclodextrin.
3. The pharmaceutical composition of claim 1 or 2, wherein a pH of said solution is above 5.5 at room temperature.
4. The pharmaceutical composition of claim 2, wherein said cyclodextrin comprises hydroxypropyl- β -cyclodextrin.
5. The pharmaceutical composition of claim 2, wherein said concentration of said cyclodextrin is from about 15% (w/v) to about 25% (w/v) of said solution.
6. The pharmaceutical composition of claim 2, wherein said concentration of said cyclodextrin is at least about 10% (w/v) of said solution.
7. The pharmaceutical composition of claim 2, wherein said concentration of said cyclodextrin is about 20% (w/v) of said solution.
8. The pharmaceutical composition of claim 1, wherein said concentration of said salt of flecainide is about 65 mg/mL to about 130 mg/mL.
9. The pharmaceutical composition of claim 1, wherein said concentration of said salt of flecainide is about 75 mg/mL.
10. The pharmaceutical composition of claim 1, wherein said salt of flecainide is selected from the group consisting of: flecainide acetate, flecainide hydrochloride, flecainide citrate, flecainide phosphate, and flecainide nitrate.

11. The pharmaceutical composition of any prior claim, wherein said salt of flecainide comprises flecainide acetate.
12. The pharmaceutical composition of claim 1, further comprising an acid.
13. The pharmaceutical composition of claim 12, wherein said acid is selected from the group consisting of: acetic acid, citric acid, nitric acid, hydrochloric acid, sulfuric acid, maleic acid, tartaric acid, phosphoric acid, aconitic acid, adipic acid, ascorbic acid, benzoic acid, caprylic acid, cholic acid, formic acid, glutamic acid, lactic acid, propionic acid, sorbic acid, stearic acid, and succinic acid.
14. The pharmaceutical composition of claim 12, wherein a concentration of said acid in said pharmaceutical composition is about 2 mM to about 50 mM.
15. The pharmaceutical composition of claim 12, wherein said concentration of said acid is about 20 mM.
16. The pharmaceutical composition of claim 12, wherein said concentration of said acid is about 5 mM.
17. The pharmaceutical composition of claim 12, wherein said acid comprises acetic acid.
18. The pharmaceutical composition of claim 17, wherein a concentration of acetic acid is about 5 mM.
19. The pharmaceutical composition of claim 12, wherein said acid comprises citric acid.
20. The pharmaceutical composition of claim 19, wherein a concentration of citric acid is about 5 mM.
21. The pharmaceutical composition of claim 12, wherein said acid comprises a mixture of acids selected from the group consisting of: acetic acid, citric acid, nitric acid, hydrochloric acid, and sulfuric acid.

22. The pharmaceutical composition of claim 3, wherein said pH of said solution is from about 5.5 to about 6.5.
23. The pharmaceutical composition of claim 3, wherein said pH of said solution is about 5.9.
24. The pharmaceutical composition of claim 1, further comprising a sweetener.
25. The pharmaceutical composition of claim 24, wherein said sweetener comprises saccharin.
26. The pharmaceutical composition of claim 24, wherein said sweetener comprises saccharin sodium.
27. The pharmaceutical composition of any prior claim, wherein said pharmaceutical composition is formulated for administration via inhalation.
28. The pharmaceutical composition of any prior claim, wherein said pharmaceutical composition is a nebulized solution that comprises nebulized droplets having a mass median aerodynamic diameter of less than 10 μm .
29. A unit dose of said pharmaceutical composition of any prior claim, comprising about 50 mg to about 350 mg of said salt of flecainide.
30. The unit dose of claim 29, comprising about 60 mg to about 150 mg of said salt of flecainide.
31. The unit dose of claim 29, comprising about 100 mg to about 250 mg of said salt of flecainide.
32. The unit dose of claim 29, comprising about 90 mg of said salt of flecainide.
33. The unit dose of claim 29, comprising about 120 mg of said salt of flecainide.

34. The unit dose of claim 29, comprising about 200 mg of said salt of flecainide.
35. A kit, comprising: said pharmaceutical composition or said unit dose of any prior claim and instructions for use of said pharmaceutical composition for treatment of a heart condition.
36. The kit of claim 35, further comprising a container containing said pharmaceutical composition.
37. The kit of claim 36, wherein said container is selected from the group consisting of: a vial, a syringe, a capsule, a blow fill seal, a blister, a cartridge, and an ampoule.
38. A kit, comprising:
- (1) a pharmaceutical composition that comprises:
 - (a) a salt of flecainide,
 - (b) a cyclodextrin, and
 - (c) an acid;
 - (2) a receptacle containing said pharmaceutical composition; and
 - (3) instructions for use of a nebulizer to inhalationally administer a dose of said pharmaceutical composition in aerosol to a subject, wherein said dose contains from about 50 mg to about 250 mg of said salt of flecainide, and said aerosol of said pharmaceutical composition has droplets that have a mass median aerodynamic diameter of less than 10 μm ; and
- wherein said pharmaceutical composition is in the form of a liquid solution that has:
- (i) said salt of flecainide at a concentration of from about 65 mg/mL to about 95 mg/mL,
 - (ii) said cyclodextrin at a concentration of from about 10% (w/v) to about 30% (w/v) of said solution; and
 - (iii) a pH of from about 5.5 to about 6.5 when said pH is measured at room temperature.
39. A system, comprising: said pharmaceutical composition of any prior claim and a nebulizer.

40. The system of claim 39, wherein said pharmaceutical composition is formulated for administration via the nebulizer, wherein the nebulizer is selected from the group consisting of a breath-actuated jet nebulizer, a vibrating mesh nebulizer, and a ultrasonic nebulizer.
41. The system of claim 39, further comprising instructions for use of said nebulizer and said pharmaceutical composition for treatment of a heart condition.
42. The system of claim 39, further comprising instructions for use of said nebulizer and said pharmaceutical composition for treatment of atrial arrhythmia.
43. The system of claim 39, wherein said nebulizer is configured to deliver said pharmaceutical composition as droplets having a mass median aerodynamic diameter of less than 10 μm .
44. The system of claim 39, wherein said nebulizer is a breath-actuated nebulizer.
45. The system of claim 39, wherein said nebulizer is a jet nebulizer.
46. The system of claim 39, wherein said instructions contain instructions for use of said nebulizer to deliver said pharmaceutical composition in a unit dose that contains about 60 mg to about 150 mg of said salt of flecainide.
47. The system of claim 39, wherein said instructions contain instructions for use of said nebulizer to deliver said pharmaceutical composition in a unit dose that contains about 75 mg to about 125 mg of said salt of flecainide.
48. A system, comprising:
 - a pharmaceutical composition that comprises a salt of flecainide, a cyclodextrin, and an acid;
 - a nebulizer configured to deliver said pharmaceutical composition as droplets having a mass median aerodynamic diameter of less than 10 μm ; and
 - instructions for use of said nebulizer to deliver said pharmaceutical composition in a unit dose that contains between about 50 mg and about 250 mg of said salt of flecainide,

wherein said pharmaceutical composition is in the form of a liquid solution that has (i) said salt of flecainide at a concentration of between 65 mg/mL and 100 mg/mL, (ii) said cyclodextrin at a concentration of between about 10% (w/v) and about 30% (w/v) of said solution; and (iii) a pH of between about 5.5 and about 6.5 at room temperature..

49. A method of treating a subject suffering from a heart condition, comprising:
administering to said subject via inhalation a pharmaceutical composition in the form of a liquid solution, wherein said pharmaceutical composition comprises a therapeutically effective amount of a salt of flecainide, and wherein a concentration of said salt of flecainide in said pharmaceutical composition is above 60 mg/mL.
50. The method of claim 49, wherein said pharmaceutical composition further comprises a cyclodextrin.
51. The method of claim 49 or 50, wherein a pH of said solution is above 5.5 when said pH is measured at room temperature.
52. A method of treating a human subject suffering from a heart condition, comprising administering to said subject via inhalation within about 10 min a pharmaceutical composition in the form of a liquid solution, wherein said pharmaceutical composition comprises a therapeutically effective amount of a salt of flecainide, and wherein said administration results in a peak plasma concentration (C_{max}) of said salt of flecainide in said subject that is at least 200 ng/mL.
53. The method of claim 52, wherein a concentration of said salt of flecainide in said pharmaceutical composition is above 60 mg/mL of said solution.
54. The method of claim 49, 52 or 53, wherein said pharmaceutical composition further comprises a cyclodextrin.
55. The method of claim 52, wherein said C_{max} is between about 250 ng/mL and about 1000 ng/mL.

56. The method of claim 52, wherein said C_{max} is between about 300 ng/mL and about 700 ng/mL.
57. The method of claim 49 or 52, wherein said administration of said pharmaceutical composition is performed within about 10 min.
58. The method of claim 49 or 52, wherein said administration of said pharmaceutical composition is performed via one or two inhalations.
59. The method of claim 49 or 52, wherein said administration of said pharmaceutical composition is performed via two inhalations that are separated by a break for from about 10 seconds to about 1 minute.
60. The method of claim 49 or 52, wherein said administration of said pharmaceutical composition is performed within about 5 min.
61. The method of claim 49 or 52, wherein said administration is performed via a nebulizer.
62. The method of claim 61, wherein said nebulizer is a breath-actuated nebulizer.
63. The method of claim 61, wherein said nebulizer is a jet nebulizer.
64. The method of claim 61, wherein said nebulizer is a vibrating mesh nebulizer.
65. The method of claim 49 or 52, wherein about 100 mg to about 250 mg of said salt of flecainide is administered to said subject via inhalation.
66. The method of claim 49 or 52, wherein about 90 mg of said salt of flecainide is administered to said subject via inhalation.
67. The method of claim 49 or 52, wherein about 120 mg of said salt of flecainide is administered to said subject via inhalation.

68. The method of claim 49 or 52, wherein about 200 mg of said salt of flecainide is administered to said subject via inhalation.
69. The method of claim 49 or 52, wherein said heart condition comprises atrial arrhythmia.
70. The method of claim 49 or 52, wherein said atrial arrhythmia comprises tachycardia.
71. The method of claim 49 or 52, comprising acute treatment after detection of said atrial arrhythmia.
72. The method of claim 49 or 52, wherein said heart condition comprises atrial fibrillation.
73. The method of claim 72, wherein said atrial fibrillation is recurrent atrial fibrillation.
74. The method of claim 72, wherein said atrial fibrillation is paroxysmal atrial fibrillation.
75. The method of claim 49 or 52, wherein said subject has a systolic blood pressure that is greater than about 90 mmHg at the time of treating.
76. The method of claim 49 or 52, wherein said subject has a systolic blood pressure that is from about 100 mmHg to about 160 mmHg at the time of treating.
77. The method of claim 49 or 52, wherein said subject has a ventricular rate that is no more than 170 BPM at the time of treating.
78. The method of claim 49 or 52, wherein said subject has a ventricular rate that is from about 80 BPM to about 155 BPM at the time of treating.
79. A method of preparing a liquid pharmaceutical composition, comprising combining:
 - (a) water;
 - (b) a pH adjusting agent;
 - (c) flecainide or a pharmaceutically acceptable salt thereof; and
 - (d) a cyclodextrin.

80. The method of claim 79, wherein:
- (i) a concentration of said flecainide or a pharmaceutically acceptable salt thereof is from about 65 mg/mL to about 95 mg/mL in said pharmaceutical composition,
 - (ii) a concentration of said cyclodextrin in said pharmaceutical composition is from about 10% (w/v) to about 30% (w/v); and
 - (iii) a room-temperature pH in said pharmaceutical composition of from about 5.5 to about 6.5.
81. The method of claims 79 or 80, wherein said combining comprises:
- (a) providing said water;
 - (b) contacting said portion of water with said flecainide or pharmaceutically acceptable salt thereof, said cyclodextrin, and said pH adjusting agent in a vessel; and
 - (c) adding a subsequent portion of said water to said vessel to provide said pharmaceutical composition, wherein:
 - (i) a concentration of said flecainide or a pharmaceutically acceptable salt thereof is from about 65 mg/mL to about 95 mg/mL in said pharmaceutical composition,
 - (ii) a concentration of said cyclodextrin in said pharmaceutical composition is from about 10% (w/v) to about 30% (w/v); and
 - (iii) a room-temperature pH in said pharmaceutical composition of from about 5.5 to about 6.5.
82. The method of claim 79, wherein said pH adjusting agent comprises an ion selected from the group consisting of: acetate, citrate, nitrate, chloride, sulfate, maleate, tartrate, phosphate, aconitate, adipate, ascorbate, benzoate, caprylate, cholate, formate, glutamate, lactate, propionate, sorbate, stearate, and succinate.
83. The method of claim 79, wherein said pH adjusting agent is selected from the group consisting of: acetic acid, citric acid, nitric acid, hydrochloric acid, sulfuric acid, maleic acid, tartaric acid, phosphoric acid, aconitic acid, adipic acid, ascorbic acid, benzoic acid, caprylic acid, cholic acid, formic acid, glutamic acid, lactic acid, propionic acid, sorbic acid, stearic acid, and succinic acid.

84. The method of claim 79, wherein said pH adjusting agent is selected from the group consisting of: acetic acid, citric acid, nitric acid, hydrochloric acid, and sulfuric acid.
85. The method of claim 79, wherein said pH adjusting agent comprises a mixture of acids selected from the group consisting of: acetic acid, citric acid, nitric acid, hydrochloric acid, and sulfuric acid.
86. The method of claim 79, wherein a concentration of said pH adjusting agent in said pharmaceutical composition is about 2 mM to about 10 mM.
87. The method of claim 79, wherein said pH adjusting agent comprises acetic acid.
88. The method of claim 87, wherein said concentration in said pharmaceutical composition of said acetic acid is about 5 mM.
89. The method of claim 79, wherein said pH adjusting agent comprises citric acid.
90. The method of claim 89, wherein said concentration in said pharmaceutical composition of said citric acid is about 5 mM.
91. The method of claim 79, wherein said cyclodextrin comprises hydroxypropyl- β -cyclodextrin.
92. The method of claim 79, wherein said concentration of said cyclodextrin in said pharmaceutical composition is from about 10% (w/v) to about 30% (w/v).
93. The method of claim 79-92, further comprising adding a sweetener.
94. The method of claim 93, wherein said sweetener comprises saccharin.
95. The method of claim 93, wherein said sweetener comprises saccharin sodium.
96. The method of claim 93, wherein a concentration of said sweetener in said pharmaceutical composition is from about 0.001% (w/v) to about 0.01% (w/v).

97. The method of claim 79, wherein said pharmaceutically acceptable salt of flecainide is added.
98. The method of claim 97, wherein pharmaceutically acceptable said salt of flecainide comprises flecainide acetate.
99. The method of claim 79, further comprising packaging said pharmaceutical composition in unit dose form.
100. The method of claim 99, wherein said unit dose form further comprises a container selected from the group consisting of: a vial, a syringe, a capsule, a blow fill seal, a blister, a cartridge, and an ampoule.